Immunovant, Inc. (IMVT)

NASDAQ: IMVT · Real-Time Price · USD

39.41

+0.04 (0.10%)

Jul 24, 2026, 4:00 PM EDT - Market closed

Immunovant Financials Overview

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Income	-532.9	-532.9	-438.15	-282.71	-218.28	-156.03
Net Income	-505.61	-505.61	-413.84	-259.34	-210.96	-156.73
Earnings Per Share	-2.77	-2.77	-2.73	-1.88	-1.71	-1.43
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Investments	902.11	902.11	713.97	635.37	376.53	493.82
Total Debt	0.07	0.07	0.1	0.14	1.22	2.36
Net Cash (Debt)	902.04	902.04	713.87	635.23	375.31	491.45
Net Cash Growth	26.36%	26.36%	12.38%	69.25%	-23.63%	23.88%
Net Cash Per Share	4.94	4.94	4.71	4.60	3.05	4.48

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Cash Flow	-407.31	-407.31	-375.87	-214.23	-188.19	-106.11
Capital Expenditures	-0.01	-0.01	-0.76	-0.36	-0.2	-0.25
Free Cash Flow	-407.32	-407.32	-376.63	-214.59	-188.39	-106.37
Free Cash Flow Growth	-	-	-	-	-	-